Biomarkers

The Undeniable Link Between the Brain and Gut

Biomarkers, Constipation, Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Probiotics, Prebiotics and Symbiotics /

Nausea, heartburn, indigestion, constipation, andstomach pain are all kinds of gastrointestinal problems we have faced before. They are easy to dismissas merely an upset stomach, but this mentality couldbuild up and ultimately be detrimental to mental and physicalhealth. Improperly caring for the digestive system can lead toextensive intestinal health issues. The microbiome is a collectionof […]

The Undeniable Link Between the Brain and Gut Read More »

Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease

Biomarkers, Metabolites, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD), as the second most common neurodegenerative disease, is seriously affecting the life quality of the elderly. However, there is still a lack of efficient medical methods to diagnosis PD before apparent symptoms occur. In recent years, clinical biomarkers including genetic, imaging, and tissue markers have exhibited remarkable benefits in assisting PD diagnoses.

Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease Read More »

The Role of Dysbiosis in Neurological Disorders

Biomarkers, Butyrate, Fecal Transplants (FMT), Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Gut-Brain axis, Metabolites, Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

The gut brain axis is a system of bi-directional communication. When the delicate balance of the microbiome is disrupted, the resulting dysbiosis can be a factor in the development of neurological disorders, including Alzheimer’s Disease (AD), Parkinson’s Disease (PK), and Multiple Sclerosis (MS). One major player in the gut brain axis are short-chain fatty acids

The Role of Dysbiosis in Neurological Disorders Read More »

Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut

Biomarkers, Gut Dysbiosis, Gut Microbiota, Parkinson's Disease, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

With the increasing amount of evidence linking certain disorders of the human body to a disturbed gut microbiota, there is a growing interest for compounds that positively influence its composition and activity through diet. Besides the consumption of probiotics to stimulate favorable bacterial communities in the human gastrointestinal tract, prebiotics such as inulin-type fructans (ITF)

Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut Read More »

Melatonin as first-line treatment for sleep disorders in Parkinson’s disease?

Biomarkers, iRBD, Pre-PD /

Sleep disturbance has been reported in up to 88%–98% of Parkinson’s disease patients; various sleep disorders can present even before motor symptoms. Rapid eye movement sleep behavior disorder (RBD), which can lead to violent dream enactment behavior, has a prevalence in Parkinson’s disease of 20% to 50% but best management of the condition is unclear.

Melatonin as first-line treatment for sleep disorders in Parkinson’s disease? Read More »

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease

A-Synuclein, Biomarkers /

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for Parkinson’s disease (PD) and related synucleinopathies. They enable detection of seeding-competent alpha-synuclein aggregates in living patients and have shown high diagnostic accuracy in several PD and other synucleinopathy patient cohorts. However, there has been confusion about αSyn-SAAs for their methodology, nomenclature, and relative accuracies when

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease Read More »

Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies

A-Synuclein, Biomarkers, Dementia - Lewy Bodies, Parkinson's Disease, Pre-PD /

The clinicopathological heterogeneity in Lewy-body diseases (LBD) highlights the need for pathology-driven biomarkers in-vivo. Misfolded alpha-synuclein (α-Syn) is a lead candidate based on its crucial role in disease pathophysiology. Real-time quaking-induced conversion (RT-QuIC) analysis of CSF has recently shown high sensitivity and specificity for the detection of misfolded α-Syn in patients with Parkinson’s disease (PD) and

Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies Read More »

Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer’s Disease Pathogenesis

Biomarkers /

Alzheimer’s disease (AD) is a neurodegenerative disease that inevitably results in dementia and death. Currently, there are no pathogenetically grounded methods for the prevention and treatment of AD, and all current treatment regimens are symptomatic and unable to significantly delay the development of dementia. The accumulation of β-amyloid peptide (Aβ), which is a spontaneous, aggregation-prone,

Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer’s Disease Pathogenesis Read More »